PMID- 28343445
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20180830
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 31
IP  - 2
DP  - 2018 Apr
TI  - A Case of Anagrelide-Induced Nonischemic Cardiomyopathy in a Patient With 
      Essential Thrombocythemia.
PG  - 230-233
LID - 10.1177/0897190017699774 [doi]
AB  - BACKGROUND: Anagrelide is an established treatment option for essential 
      thrombocythemia (ET). Cardiovascular adverse events can occur with its use 
      including heart failure and cardiomyopathy. CASE REPORT: A 52-year-old African 
      American male with ET presented with chest pain, shortness of breath, and dyspnea 
      on exertion. His ET was managed with hydroxyurea 1500 mg by mouth twice a day and 
      anagrelide 1 mg by mouth 3 times a day. The patient was receiving anagrelide for 
      approximately 2 years prior to presentation. The patient's platelet count was 
      2.07 x 10(5) cells/mm(3). Transthoracic echocardiography revealed decreased left 
      systolic dysfunction. Also, cardiac magnetic resonance imaging showed an 
      increased left ventricle cavity size with severely depressed systolic dysfunction 
      and an ejection fraction (EF) of 18%. Anagrelide therapy was discontinued and the 
      patient was maintained on hydroxyurea for ET. Three months later, following 
      treatment by a heart failure clinic, the patient's EF was 55%. Five months after 
      discontinuation, the patient improved from New York Heart Association (NYHA) 
      class II to NYHA class I. CONCLUSION: A 52-year-old man with ET presented with an 
      EF of 18% after 2 years of anagrelide therapy. His EF increased from 18% to 55% 3 
      months after discontinuation of anagrelide.
FAU - Singh, Pritpal
AU  - Singh P
AD  - 1 Department of Pharmacy, St Peter's Hospital, Albany, NY, USA.
AD  - 2 Division of Pharmacovigilance II, Office of Surveillance and Epidemiology, 
      Center for Drug Evaluation and Research, US Food and Drug Administration, Silver 
      Spring, MD, USA.
AD  - Current affiliation.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170327
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Quinazolines)
RN  - K9X45X0051 (anagrelide)
SB  - IM
MH  - Cardiomyopathies/*chemically induced/*diagnostic imaging
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Quinazolines/*adverse effects
MH  - Thrombocythemia, Essential/*diagnostic imaging/*drug therapy
OTO - NOTNLM
OT  - anagrelide
OT  - essential thrombocythemia
OT  - heart failure
EDAT- 2017/03/28 06:00
MHDA- 2018/08/31 06:00
CRDT- 2017/03/28 06:00
PHST- 2017/03/28 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
PHST- 2017/03/28 06:00 [entrez]
AID - 10.1177/0897190017699774 [doi]
PST - ppublish
SO  - J Pharm Pract. 2018 Apr;31(2):230-233. doi: 10.1177/0897190017699774. Epub 2017 
      Mar 27.